Clinical Trial Update: PF-06651600 for the Treatment of Alopecia Areata [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update for PF-06651600 in Alopecia Areata has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• PF-06651600 (PF-06651600)

Snippet

Sponsor: Pfizer | Conditions: Alopecia Areata | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-02-24